Based on the Avenue Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Avenue Therapeutics Inc is not available over the next 12 months. Avenue Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Avenue Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Avenue Therapeutics Inc’s stock price was USD 2.10. Avenue Therapeutics Inc’s stock price has changed by -0.94% over the past week, -12.13% over the past month and +5,152.63% over the last year.
No recent analyst target price found for Avenue Therapeutics Inc
No recent average analyst rating found for Avenue Therapeutics Inc
Company Overview Avenue Therapeutics Inc
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. Address: 1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154 Read Less
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bu...Read More
Frequently Asked Questions About Avenue Therapeutics Inc (ATXI) Stock
Stock Target Advisor's fundamental analysis for Avenue Therapeutics Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on ATXI's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ATXI's stock to indicate what its average analyst target is.
ATXI stock's Price/Earning ratio is 0.06.
Our analysis grades ATXI stock's Price / Earning ratio at B+. This means that ATXI stock's Price/Earning ratio is above 12% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ATXI may be undervalued for its sector.
The last closing price of ATXI's stock was USD 2.10.
The most recent market capitalization for ATXI is USD 3.02M.
Unfortunately we do not have enough analyst data on ATXI's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Avenue Therapeutics Inc's stock.
As per our most recent records Avenue Therapeutics Inc has 3 Employees.
Avenue Therapeutics Inc's registered address is 1111 Kane Concourse, Tampa, FL, United States, 33154.
You can get more information about it from Avenue Therapeutics Inc's website at https://www.avenuetx.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Avenue Therapeutics Inc (ATXI) Stock
Stock Target Advisor's fundamental analysis for Avenue Therapeutics Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on ATXI's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ATXI's stock to indicate what its average analyst target is.
ATXI stock's Price/Earning ratio is 0.06.
Our analysis grades ATXI stock's Price / Earning ratio at B+. This means that ATXI stock's Price/Earning ratio is above 12% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ATXI may be undervalued for its sector.
The last closing price of ATXI's stock was USD 2.10.
The most recent market capitalization for ATXI is USD 3.02M.
Unfortunately we do not have enough analyst data on ATXI's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Avenue Therapeutics Inc's stock.
As per our most recent records Avenue Therapeutics Inc has 3 Employees.
Avenue Therapeutics Inc's registered address is 1111 Kane Concourse, Tampa, FL, United States, 33154.
You can get more information about it from Avenue Therapeutics Inc's website at https://www.avenuetx.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ATXI !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
